Natasha Leighl, MD, University of Toronto, Toronto, Canada, gives an overview of results from the Phase Ib PALMOA trial (NCT0406381) of subcutaneous amivantamab in patients with advanced solid tumors. Traditional intravenous administration of amivantamab can take a long time, and over multiple sessions, and subcutaneous administration was investigated as a potential alternative route of administration. Patients reported fewer adverse events and was overall well tolerated. Further assessment will take place in the PALOMA-2 (NCT05498428) and PALOMA-3 (NCT05388669) trials. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
